Low-molecular-weight heparins: Pharmacologic profile and product differentiation

American Journal of Cardiology

Volumn 82, Issue 5 B, 1998, Pages 3L-10L

  Fareed, Jawed ^a   Jeske, Walter ^a   Hoppensteadt, Debra ^a   Clarizio, Rana ^a   Walenga, Jeanine M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTAMINE; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICOAGULANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0032505019     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00105-2     Document Type: Conference Paper

References (29)

1. Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985;11:155-175.
2. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of 7 low molecular weight heparins. Haemostasis 1989;18:3-15.
3. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G. Low-molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
4. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost 1997;77:32-38.
5. Abildgard U, Sandset P, Lindahl A. Tissue factor pathway inhibitor. In: Poller L, ed. Recent Advances in Blood Coagulation. New York: Churchill-Livingstone, 1993:105-124.
6. Broze GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995;6:S7-S13.
7. Hoppensteadt DA, Jeske W, Fareed J, Bermes Jr EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995;6(suppl 1):S57-S64.
8. Brieger D, Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-322.
9. Hansen J-B, Sandse PM, Huseby KR, Huseby N-E, Nordoy A. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996;76: 703-709.
10. Van Dedum G, Nielsen JI. Determinations of the molecular mass of low molecular mass (LMM) heparin. Pharmeuropa 1991;3:202-218.
11. Raake W, Elling H. Rat jugular vein hemostasis a new model for testing antithrombotic agents. Thromb Res 1989;53:73-77.
12. Cade JF, Buchanan MR, Boneu B, Ockelford P. A comparison of the anti-thrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the preparation. (Abstr.) Thromb Res 1984;35:613.
13. Fareed J, Kumar A, Rock A, Walenga JM, Davis P. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions. (Abstr.) Semin Thromb Haemost 1985;11:138.
14. Racanelli A. Biochemical and pharmacological studies on the interaction of protamine with heparins. Unpublished Ph.D. Thesis, January, 1990.
15. Samama M. Contemporary laboratory monitoring of low molecular weight heparins. Thromb Haemost 1995;15:119-123.
16. Abbate R, Gori AM, Alessandro F, Monica A, Guglielmina P. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998;82: 33L-36L.
17. Fareed J. Current trends in antithrombotic drug and device development. Semin Thromb Hemost 1996;22:3-8.
18. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Hemost 1995;74:360-363.
19. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenz J, Schmid KM, Betz E, Karsch KR. Inhibition of cellular proliferation after experimental balloon angioplasty by low molecular weight heparin. Circulation 1992;85:1548-1556.
20. Schmid KM, Preisack M, Voelker W, Sujatta M, Karsch KR. First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost 1993;19:155-159.
21. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Frommell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
22. The Columbus investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662.
23. Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing surgery: report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis 1993;4:821-S22.
24. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, Laurent M, Hirsch JL, Ferrari E, Bosson JL, Mottier D, Beau B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997;337:663-669.
25. Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, Silsiguen M, Combe S. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-1546.
26. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 1997;96:61-68.
27. FRISC study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
28. Armstrong PW. Heparin in acute coronary disease requiem for a heavy-weight? N Engl J Med 1997;337:492-494.
29. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ. Comparison of the pharmacokinetic profiles of three low molecular mass heparins dalteparin, enoxaparin and nadroparin administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-640.